The chart above plots the price of CTNM over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 46 sessions over that window: $13.39 on 20 May 2026 through $14 on 27 July 2026.
Market cap$323.4M
52-week range$5 – $16
Avg volume82.8K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
CTNM insider trades
SEC Form 4 · last 90 days · newest reported trade 3 Aug 2026
Open-market buys0
Open-market sells9
Net sold$1.08M
Non-trade filings8
DateInsiderTypeSharesValue
03 Aug 2026Stengone Carmine N.CEO and PresidentSell2,500$40K
09 Jul 2026Lorrain Daniel S.Chief Scientific OfficerSell25$0K
08 Jul 2026Stengone Carmine N.CEO and PresidentSell2,500$40K
08 Jul 2026Lorrain Daniel S.Chief Scientific OfficerSell1,015$16K
01 Jul 2026Lorrain Daniel S.Chief Scientific OfficerSell8,353$132K
30 Jun 2026Lorrain Daniel S.Chief Scientific OfficerSell28,826$462K
30 Jun 2026Stengone Carmine N.CEO and PresidentSell10,000$160K
30 Jun 2026Watkins TimCMO & Head of DevelopmentSell10,833$174K
01 Jun 2026Lorrain Daniel S.Chief Scientific OfficerSell4,170$55K
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
03 Aug 2026Stengone Carmine N.CEO and PresidentOption exercise2,500$3K
09 Jul 2026Lorrain Daniel S.Chief Scientific OfficerOption exercise25$0K
08 Jul 2026Stengone Carmine N.CEO and PresidentOption exercise2,500$3K
08 Jul 2026Lorrain Daniel S.Chief Scientific OfficerOption exercise1,015$1K
01 Jul 2026Lorrain Daniel S.Chief Scientific OfficerOption exercise4,183$4K
30 Jun 2026Lorrain Daniel S.Chief Scientific OfficerOption exercise28,826$29K
30 Jun 2026Stengone Carmine N.CEO and PresidentOption exercise10,000$11K
30 Jun 2026Watkins TimCMO & Head of DevelopmentOption exercise10,833$49K
CTNM reported financials
SEC EDGAR XBRL
CTNM reported net income of −$60.0M for the fiscal year ended 31 Dec 2025.
FigureReportedPeriod
Net income
−$60.0M
31 Dec 2025 fiscal year
Diluted EPS
−$2.17
31 Dec 2025 fiscal year
Total assets
$250.4M
30 Jun 2026 at period end
Total equity
$239.7M
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
CTNM earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$-0.40—
31 Mar 2026Q1 2026$-0.39—
31 Dec 2025FY 2025$-2.17—
30 Jun 2025Q2 2026$-0.62—
31 Mar 2025Q1 2026$-0.62—
31 Dec 2024FY 2024$-2.18—
30 Sep 2024Q3 2024$-0.40—
30 Jun 2024Q2 2024$-0.39—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
CTNM institutional holders
SEC Form 13F
7 of the 45 institutional funds we track reported a CTNM position for the quarter ended 30 Jun 2026 — a combined $50.7M; the latest of those filings landed 14 Aug 2026.